David Duggan, Ph.D.

Director, Human Population Genetics Lab Director, Advanced Genomics Technology Center
Associate Professor, Genetic Basis of Human Disease Division
Translational Genomics Research Institute (TGEN)

Dr. Duggan is a graduate of the University of Pittsburgh with a doctorate degree in human genetics. He did his post‐doctoral studies at the National Human Genome Research Institute (NHGRI, National Institutes of Health, Bethesda, MD, USA) and later moved to an Associate Investigator position at the National Institute of Arthritis and Muscoloskeletal and Skin Diseases before relocating his laboratory to TGen in 2003.

Dr. Duggan has 23 years of experience in the fields of human genetics and genomics with an emphasis on inherited predisposition and population genetic risk factors. Research in his laboratory focuses on determining the genetic basis of human disease through the use of family- and population-based study designs incorporating state-of‐the‐art study designs, technological approaches and high-throughput, wide-reaching technologies.

The core strength of Dr. Duggan’s research resides in his scientific collaborations, knowledge and application of state-of-the-art technologies, and an ability to integrate with teams including clinicians, epidemiologists, mathematicians, statisticians, bioinformaticians, and laboratory scientists. Through partnerships with numerous national and international collaborators, his research seeks to identify biomarkers in germline DNA related to risk prediction, diagnosis, prognosis, and or treatment. Current collaborations include the National Cancer Institute’s (NCI) Breast and Colon Cancer Family Registries (B/CCFR), NHGRI’s Population Architecture Using Genomics and Epidemiology (PAGE), NCI’s Women’s Environment, Cancer, and Radiation Epidemiology (WECARE), and the National Heart, Lung, and Blood Institute supported Women’s Health Initiative (WHI). Diseases currently being studied include common, complex diseases such as cancer (e.g., breast, colon, and prostate), cardiovascular disease (e.g., HDL and LDL genetics), and women’s health related diseases (e.g., bone mineral disease). 

Candidate gene and genome-wide association studies as well as targeted, exome, and whole genome sequencing studies are frequently being applied to these complex diseases in an effort to elucidate their genetic etiology. His laboratory is familiar with all aspects of biomarkers as they pertain to genotyping and sequencing including microsatellites, SSTRs, VNTRs, RFLPs, insertions, deletions, SNPs, and Sanger and next generation sequencing (e.g., targeted, whole exome, and whole genome). More than 300,000 samples have been studied in the last 8 years. His laboratory has contributed to >120 peer-reviewed publications in the areas of genetic mapping, disease gene identification (4 to date), candidate SNP, gene, and genome-wide associations, gene expression profiling and next generation sequencing. In addition, Dr. Duggan has contributed to 6 subject matter expertise reviews, 3 book chapters, and 1 book (Oncogenomics: Molecular Approaches to Cancer; Wiley & Sons, Inc.).